USFDA approves ‘Female Viagra’

The pink pill, when ingested daily, is said to boost certain brain chemicals in women

sprout3-bz-080515-hll

Ms Cindy Whitehead, CEO, Sprout Pharmaceuticals (Photo Courtesy: www.newsobserver.com)

US-based Sprout Pharmaceuticals gained USFDA's approval for Addyi, whose chemical name is Flibanserin, created to enhance sex drive in premenopausal women or women suffering from hypoactive sexual desire disorder (HSDD).

Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States, voiced Sprout.

The approval has been granted with strong warnings of effects including low blood pressure and fainting when taken with alcohol.

The company said, the most common adverse events among patients treated with Addyi were dizziness, somnolence, nausea, fatigue, insomnia and dry mouth.

Hypotension and syncope were seen rarely with Addyi alone but more frequently when Addyi was taken in the morning and when co-administered with alcohol or certain other drugs.

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X